RxDoctor Payments Data

Imola Daniel, MD

Internal Medicine · Worcester, MANPI 1245460609

Payments from drug & device makers

$15,963in general payments, 2019–2025

Across 708 payments — averaging $22.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Gilead$1K
  • AstraZeneca$1K
  • Pfizer$1K
  • Johnson & Johnson$1K
  • Lilly USA, LLC$1K
  • plus $9K from 54 others

What the payments were for

  • Food & beverage$15,950100%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)64$1,433
Gilead45$1,275
AstraZeneca58$1,162
Pfizer63$1,157
Johnson & Johnson(2 entities)36$1,064
Lilly USA, LLC47$1,056
Boehringer Ingelheim26$619
GSK30$604
Novartis28$579
Novo Nordisk23$526
Viiv Healthcare Company22$509
Amgen22$504
Alnylam Pharmaceuticals Inc.18$473
Merck21$382
E.r. Squibb & Sons, L.L.C.17$354
Bayer19$352
Inspire Medical Systems, Inc.20$294
Exact Sciences10$263
Phathom Pharmaceuticals, Inc.11$255
Kiniksa Pharmaceuticals International, PLC9$221
Abiomed6$179
Takeda Pharmaceuticals U.S.A., Inc.7$156
Aimmune Therapeutics, Inc.6$137
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC6$136
Nestle Healthcare Nutrition Inc.5$123
Janssen Products, LP1$119
Abbott5$110
Sumitomo Pharma America, Inc.4$110
Bridgebio Pharma, Inc.4$110
Esperion Therapeutics, Inc.6$105
Otsuka America Pharmaceutical, Inc.4$104
Insmed, Inc.5$100
Daiichi Sankyo Inc.5$93
Biohaven Pharmaceutical Holding Company Ltd.4$92
Astellas Pharma US Inc3$90
Dexcom, Inc.3$73
Actelion Pharmaceuticals US, Inc.2$71
Invivyd Inc2$65
Scpharmaceuticals Inc.3$64
Kiniksa Pharmaceuticals, Ltd.3$59
Vertex2$59
Theratechnologies Inc.2$59
Valinor Pharma, LLC2$48
Corium, LLC2$45
Kowa Pharmaceuticals America, Inc.3$45
Braintree Laboratories, Inc.2$44
Alcresta Therapeutics, Inc.2$43
Melinta Therapeutics, LLC1$43
Eisai Inc.2$43
Ardelyx, Inc.2$39
Agios Pharmaceuticals, Inc.1$30
Ultragenyx Pharmaceutical Inc.1$28
Madrigal Pharmaceuticals1$28
Baxter Healthcare1$28
Redhill Biopharma Inc.1$24
Antares Pharma, Inc.1$23
Lundbeck LLC1$21
Shield Therapeutics Inc1$21
Paratek Pharmaceuticals, Inc.1$20
Teva Pharmaceuticals USA, Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,963 in reported general payments places this provider in the 90th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$89,796
Medicare patients
192
Services billed
747

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin116$126,270
TrulicityDulaglutide102$111,317
EliquisApixaban72$72,451
BiktarvyBictegrav/Emtricit/Tenofov Ala13$47,461
GenvoyaElviteg/Cob/Emtri/Tenof Alafen12$47,011
MounjaroTirzepatide41$44,956
Trelegy ElliptaFluticasone/Umeclidin/Vilanter60$44,112
OzempicSemaglutide46$43,420
FarxigaDapagliflozin Propanediol33$24,274
Daptomycin16$23,203
LinzessLinaclotide33$22,537
Breo ElliptaFluticasone/Vilanterol48$21,691
XareltoRivaroxaban16$20,001
Fosfomycin Tromethamine22$19,217
Dexlansoprazole DrDexlansoprazole42$15,467

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$1,056$156,273143 claims
Boehringer IngelheimJardiance$619$126,270116 claims
GileadBiktarvy, Genvoya$1,275$94,47225 claims
PfizerEliquis$1,157$72,45172 claims
GSKTrelegy Ellipta, Breo Ellipta$604$65,803108 claims
Novo NordiskOzempic$526$43,42046 claims
AstraZenecaFarxiga, Brilinta$1,162$34,48651 claims
AbbVieLinzess, Creon$1,433$25,47748 claims
Johnson & JohnsonXarelto$1,064$20,00116 claims
Redhill Biopharma Inc.Movantik$24$12,98630 claims
Astellas Pharma US IncMyrbetriq$90$11,71826 claims
NovartisEntresto$579$8,81513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Worcester

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →